Hyperuricemia is associated with secondary hyperparathyroidism in patients with chronic kidney disease

Costa, Tiago Emanuel M; Lauar, Julia C; Innecchi, Mariana L R; Coelho, Venceslau A; Moysés, Rosa Maria Affonso; Elias, Rosilene Motta

doi:10.1007/s11255-022-03116-5

Cited by 6 publications

(4 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is widely believed that purine metabolism has been associated with both obesity and hypertension, and may thereby participate in the causal effect of obesity on blood pressure regulation. [3][4][5] As the final enzyme product of purine metabolism, uric acid (UA) levels in serum have been associated with many diseases, 6 including metabolic syndrome, 7 diabetes mellitus, 8 dyslipidemia, 9 chronic kidney disease, 10 and liver dysfunctions. 11 Recent studies have demonstrated that serum UA levels are also associated with obesity 6,12 and are considered a predictor of cardiovascular disorders 13 including hypertension.…”

Section: Introductionmentioning

confidence: 99%

Elevated Uric Acid Mediates the Effect of Obesity on Hypertension Development: A Causal Mediation Analysis in a Prospective Longitudinal Study

Hong¹,

Zhang²,

Chen³

et al. 2022

CLEP

View full text Add to dashboard Cite

Although elevated uric acid is associated with obesity and considered a predictor of hypertension, the causal linkage between the three metabolic conditions is not very clear. We aim to examine whether elevated uric acid mediates the effects of obesity on hypertension development. Methods: A total of 1984 participants (mean aged 53 years, 62.10% female) with repeated measurements of obesity, blood pressure, and uric acid 4 years apart in the Gusu cohort were included. We first applied cross-lagged panel analysis and bidirectional association analysis to delineate the temporal association between obesity and hyperuricemia. Then, a causal mediation model was constructed to further examine the causal role of hyperuricemia in the linkage between obesity and hypertension. Age, sex, education, cigarette smoking, alcohol consumption, fasting blood glucose, and lipids were adjusted. Results: The cross-lagged panel analysis demonstrated that the relationship from baseline obesity to follow-up hyperuricemia was stronger than that from baseline hyperuricemia to follow-up obesity (β: 0.09 vs 0.06, P<0.01 for BMI, β: 0.13 vs 0.07, P<0.01 for WC). Bidirectional association analysis found that baseline obesity predicted the risk of incident hyperuricemia (OR = 1.09, P<0.01 for BMI, OR = 1.05, P<0.01 for WC), but the other directional association was not statistically significant (all P>0.05). The causal mediation analysis found that hyperuricemia partially mediated the association of baseline BMI (mediate proportion: 3.09%, 95% CI: 0.97%~6.00% for SBP, 3.74%, 95% CI: 1.55%~7.00% for DBP) and baseline WC (mediate proportion: 5.56%, 95% CI: 2.01% ~11.00% for SBP, 5.81%, 95% CI: 2.59%~10.00% for DBP) with follow-up blood pressures. Conclusion: Obesity preceded hyperuricemia and the latter partially mediated the relationship between obesity and hypertension, independent of behavioral and other metabolic factors.

show abstract

Section: Introductionmentioning

confidence: 99%

Elevated Uric Acid Mediates the Effect of Obesity on Hypertension Development: A Causal Mediation Analysis in a Prospective Longitudinal Study

Hong¹,

Zhang²,

Chen³

et al. 2022

CLEP

View full text Add to dashboard Cite

show abstract

“…Costa et al conducted a retrospective study of not on HD 922 ≥ 3 stage CKD patients of Caucasian origin and reported the rate of hyperuricemia as 62.4% and the presence of hyperuricemia was found to be an independent predictor of secondary hyperparathyroidism. 15 In a study of Japanese CKD patinets not on HD, the prevalence of hyperuricemia was reported to be 70.4% and 50.4% in patients with CKD stage G5 and G4, respectively. 16 Abderraman et al reported 15.2% prevalence of hyperuricemia in a study of 712 hospitalized CKD patients in N'Djamena (Chad).…”

Section: Discussionmentioning

confidence: 99%

Prevalence of Hyperuricemia in Thrice Weekly Hemodialysis Patients

Moon

Alam

Yaqoob³

et al. 2022

Pak J Kidney Dis

View full text Add to dashboard Cite

Background: Hyperuricemia is a well-established prognostic marker for chronic kidney disease (CKD) patients. Therefore, in this study, our aim was to determine the prevalence of hyperuricemia in thrice-weekly hemodialysis patients at a tertiary care hospital in Karachi, Pakistan. Methods: This was a descriptive cross-sectional study that included consecutive patients diagnosed with end-stage renal disease (ESRD) on maintenance thrice-weekly hemodialysis (HD). Based on serum urate concentrations, hyperuricemia was labeled in male patients with > 7 mg/dL, and in female patients, the threshold value was >6 mg/dL. Results: The study included a total of 73 thrice-weekly hemodialysis patients out of which 64.4% (47) were male and mean age of the study sample was 50.3 ± 12.1 years. Hyperuricemia was observed in 76.7% (56) of the patients. Females (41.1% vs. 17.6%), diabetes (46.4% vs. 23.5%), and glomerulonephritis (5.4% vs. 0%) were relatively more common among patients with hyperuricemia than non- hyperuricemia patients, respectively. Similarly, severe left ventricular (LV) dysfunction (75% vs. 35.3%), severe mitral regurgitation (14.3% vs. 5.9%), and severe tricuspid regurgitation (12.5% vs. 5.9%) were relatively more common among patients with hyperuricemia than non- hyperuricemia patients, respectively. Conclusion: Hyperuricemia was prevalent in more than 3/4th of the thrice-weekly hemodialysis patients. Females, diabetics, glomerulonephritis, severe LV dysfunction with mitral regurgitation (severe) and tricuspid regurgitation (severe) were relatively more common among hyperuricemic patients.

show abstract

“…The current study found that CKD patients with gout have higher prevalences of CKDmetabolic bone disease and degenerative joint disease, indicating that these patients may be particularly vulnerable to bone and joint damage. Prior studies reported higher PTH levels with hyperuricemia in patients with [22][23][24] and without [24][25][26] CKD, possibly due to the suppression of 1α-hydroxylase [27]. However, the causative factor in this relationship remains unclear as PTH may inhibit renal urate excretion [24].…”

Section: Discussionmentioning

confidence: 99%

Prevalence and Influence of Gout in Patients with Advanced Chronic Kidney Disease: Findings of a Large Retrospective Chart Review

Stern,

Johnson,

Shakouri

et al. 2024

GUCDD

View full text Add to dashboard Cite

Gout patients have higher mortality, heavier comorbidity burden, and lower quality of life than non-gout patients, but information is sparse on how gout affects advanced CKD patients. This study examined the prevalence and potential health impacts in stage 3–5 CKD patients. Gout was defined as being listed as a comorbidity, ULT use, and/or reported gout symptoms (tophi, >1 flare). Uncontrolled gout was defined as hyperuricemia (serum urate >6 mg/dL) with tophi, ≥2 gout flares/year, or ≥1 swollen/tender joint. This study included 746 patients (55% men, age: 56.2 ± 18.3 years, CKD-duration: 4.0 ± 4.8 years, eGFR: 32.2 ± 15.5 mL/min/1.73 m2), of which 23% met the gout criteria. Prevalence was highest in patients with stage 3b and 4 CKD. Gout patients had a significantly higher prevalence of cardiovascular comorbidities, CKD-mineral bone disorder, and back pain than non-gout patients. Uncontrolled gout patients had more hypertension, joint issues, chronic pain, febuxostat use, and colchicine use than controlled patients. Compared to those without gout, gout patients had higher rates of cardiovascular and bone diseases, with uncontrolled patients having an even higher burden. In conclusion, these data suggest that identifying and monitoring gout in CKD patients provides health benefits. However, more than one-third of gout patients did not have a formal gout diagnosis in their medical record.

show abstract

Hyperuricemia is associated with secondary hyperparathyroidism in patients with chronic kidney disease

Cited by 6 publications

References 34 publications

Elevated Uric Acid Mediates the Effect of Obesity on Hypertension Development: A Causal Mediation Analysis in a Prospective Longitudinal Study

Elevated Uric Acid Mediates the Effect of Obesity on Hypertension Development: A Causal Mediation Analysis in a Prospective Longitudinal Study

Prevalence of Hyperuricemia in Thrice Weekly Hemodialysis Patients

Prevalence and Influence of Gout in Patients with Advanced Chronic Kidney Disease: Findings of a Large Retrospective Chart Review

Contact Info

Product

Resources

About